Stockreport

Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF Data demonstrated that patients with a DecisionDx-Melanoma Class 1A (low risk) test result had a five-year recurrence-free survival rate and distant metastasis-free surv [Read more]